InvestWiser

Gentian Diagnostics AS

GENTOslo BørsHealthcareMarket value 606 m NOK
39.20NOK 0.0%
last day · Price as of 18 November 2026

The answer first

Does Gentian Diagnostics beat the market?

No, Gentian Diagnostics has not beaten the market over the last year.

Gentian Diagnostics−27.5%Oslo Børs (OSEBX)+29.5%
  • The ranking · Quality, value and trend combined

    Better than 38% of Nordic stocks

    • Quality62
    • Value21
    • Trend54

    No. 84 of 195 in healthcare

  • Expectations in the price

    High expectations

    For the share to return about 9% a year from today's price, the cash Gentian Diagnostics keeps must grow about 13% a year for 10 years.

Max for seven days

Follow Gentian Diagnostics with Aurora

Aurora lets you know at the next report. No card.

Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.

Follow your thesis

Follow your thesis on Gentian Diagnostics

From today, at a price of 39.20 NOK. Write why you follow Gentian Diagnostics, and choose what Aurora should tell you about.

What should Aurora follow?

Free, no card. The mission is ready when your account is.

Aurora tells you that something happened. What you do is your choice.

Ask Aurora about Gentian Diagnostics

Your first answer is free, no account needed.

Do you own Gentian Diagnostics, or are you thinking about it?

See it next to the rest of your portfolio, or build your first one with Gentian Diagnostics and a few more. Free, no card.

Past year against the exchange and Super Stock
Gentian Diagnostics−27.5%Oslo Børs (OSEBX)+29.5%Super Stock+44.6%
17 November 202518 November 2026
All start at 0 % a year ago, with dividends. Super Stock is our model portfolio: the 20 highest-ranked Nordic stocks on quality, value and trend.

In short

  • Gentian Diagnostics has fallen 27.5% over the past year, including dividends.
  • Overall, Gentian Diagnostics ranks better than 38% of Nordic stocks on quality, value and trend.
  • The largest fall over the past three years was 58.4%. The price is 53.4% below its peak now.

Who owns Gentian Diagnostics? See the major shareholders and their stakes

What do analysts think of Gentian Diagnostics?

Quality, value and trend

Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.

38

Quality, value and trend together. Better than 38% of Nordic stocks.

No. 84 of 195 in healthcare

Quality62
The company · Fundamentals: the accounts

Medium An average company: the accounts are neither especially strong nor weak.

No. 102 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50

  • Debt to equityBorrowings divided by equity0.19
  • Asset turnoverSales divided by everything the company owns0.82
  • Return on equityProfit divided by equity−2.7%
  • Cash conversionOperating cash flow divided by profit–

The ranking is built on equity ratio, ROA and how steadily profit grows.

Value21
The price · Valuation: the multiples

Low High price: buyers pay a lot today, often because they expect growth.

No. 96 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50

  • P/BPrice divided by equity3.1
  • P/SPrice divided by sales3.1
  • P/EPrice divided by earningsnegative earnings
  • P/CFPrice divided by operating cash flow23.8

The ranking is built on P/E, P/B and P/S.

Trend54
The share price · Technical: the price trend

Medium The share price has moved about like most stocks over the last year.

No. 71 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50

  • 3 months+1.0%
  • 6 months+9.5%
  • 9 months−0.7%
  • 12 months−27.5%

The ranking is built on 3, 6 and 12–1 months.

Return and risk

1 month
−2.0%
3 years, per year
−0.4%
5 years, per year
−11.6%
Year to date
−29.6%
Largest fall, 3 years
−58.4%
From a peak to the bottom
From the peak now
−53.4%
How far the price is from the peak
Volatility, 1 year
51.9%
How much the price swings over a year
Beta, 1 year
0.02
How much the price moves when the market moves

Return with dividends reinvested.

The funds that own Gentian Diagnostics

One fund we follow owns Gentian Diagnostics. The share is how much of the fund the stock makes up.

  • Sweden1

From the funds' latest known holdings.

About Gentian Diagnostics

Gentian Diagnostics AS is a company in healthcare, listed on Oslo Børs. The share trades in NOK. It has around 63 employees.

Gentian Diagnostics ASA develops, manufactures, and sells biochemical reagents for use in medical diagnostics and research in the United States, Asia, and Europe. It offers in-vitro diagnostic reagents for clinical chemistry analyzers, such as Gentian Calprotectin Immunoassay, a turbidimetric assay used for the measurement of circulating calprotectin in plasma and serum for detection and assessment of inflammation; Gentian Cystatin C Immunoassay test kit, a GFR marker for the diagnosis and therapeutic control of renal function and chronic kidney disease; Gentian Retinol-Binding Protein Immunoassay for detection of retinol-binding protein in human serum and plasma; and Canine CRP Immunoassay…

See the full analysis of Gentian Diagnostics.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

Free forever · No card

Other healthcare stocks on Oslo Børs

Explore the stock market